N Montagne

Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial

J. Durant, Philippe Clevenbergh, Philippe Halfon et al. · The Lancet · 1999 · 762 citations

Life Sciences, Pharmacotherapy, Molecular Virology +15

Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study

Caroline Charlier, Élodie Perrodeau, Alexandre Leclercq et al. · The Lancet Infectious Diseases · 2017 · 577 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +12

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

J. Durant, Philippe Clevenbergh, R. Garraffo et al. · AIDS · 2000 · 223 citations

Pharmacy, Pharmacokinetics, Pharmacotherapy +17

Persisting Long-Term Benefit of Genotype-Guided Treatment for HIV-Infected Patients Failing Haart. The Viradapt Study: Week 48 Follow-Up

Philippe Clevenbergh, J. Durant, Philippe Halfon et al. · Antiviral Therapy · 2000 · 114 citations

Life Sciences, Pharmacotherapy, Molecular Virology +16

Virologically suppressed patients with asymptomatic and symptomatic <scp>HIV</scp>‐associated neurocognitive disorders do not display the same pattern of immune activation

Matteo Vassallo, J. Durant, Christine Lebrun‐Frénay et al. · HIV Medicine · 2015 · 33 citations · Full text

Medicine, Immunology, Infectious Diseases +14